International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
Identifieur interne : 000471 ( PascalFrancis/Corpus ); précédent : 000470; suivant : 000472International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
Auteurs : Antonio Palumbo ; S. Vincent Rajkumar ; Jesus F. San Miguel ; Alessandra Larocca ; Ruben Niesvizky ; Gareth Morgan ; Ola Landgren ; Roman Hajek ; Hermann Einsele ; Kenneth C. Anderson ; Meletios A. Dimopoulos ; Paul G. Richardson ; Michele Cavo ; Andrew Spencer ; A. Keith Stewart ; Kazuyuki Shimizu ; Sagar Lonial ; Pieter Sonneveld ; Brian G. M. Durie ; Philippe Moreau ; Robert Z. OrlowskiSource :
- Journal of clinical oncology [ 0732-183X ] ; 2014.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Purpose To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. Methods A comprehensive review of the literature on diagnostic criteria is provided, and treatment options and management of adverse events are summarized. Results Patients with symptomatic disease and organ damage (ie, hypercalcemia, renal failure, anemia, or bone lesions) require immediate treatment. The International Staging System and chromosomal abnormalities identify high- and standard-risk patients. Proteasome inhibitors, immunomodulatory drugs, corticosteroids, and alkylating agents are the most active agents. The presence of concomitant diseases, frailty, or disability should be assessed and, if present, treated with reduced-dose approaches. Bone disease, renal damage, hematologic toxicities, infections, thromboembolism, and peripheral neuropathy are the most frequent disabling events requiring prompt and active supportive care. Conclusion These recommendations will help clinicians ensure the most appropriate care for patients with myeloma in everyday clinical practice.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 14-0114004 INIST |
|---|---|
| ET : | International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation |
| AU : | PALUMBO (Antonio); VINCENT RAJKUMAR (S.); SAN MIGUEL (Jesus F.); LAROCCA (Alessandra); NIESVIZKY (Ruben); MORGAN (Gareth); LANDGREN (Ola); HAJEK (Roman); EINSELE (Hermann); ANDERSON (Kenneth C.); DIMOPOULOS (Meletios A.); RICHARDSON (Paul G.); CAVO (Michele); SPENCER (Andrew); KEITH STEWART (A.); SHIMIZU (Kazuyuki); LONIAL (Sagar); SONNEVELD (Pieter); DURIE (Brian G. M.); MOREAU (Philippe); ORLOWSKI (Robert Z.) |
| AF : | University of Torino/Torino/Italie (1 aut., 4 aut.); Seragnoli Institute of Hematology, Bologna University School of Medicine/Bologna/Italie (13 aut.); Mayo Clinic/Rochester, MN/Etats-Unis (2 aut.); University Hospital of Salamanca/Salamanca/Espagne (3 aut.); Weill Cornell Medical College/New York, NY/Etats-Unis (5 aut.); Royal Marsden Hospital/London/Royaume-Uni (6 aut.); National Cancer Institute/Bethesda, MD/Etats-Unis (7 aut.); University of Ostrava School of Medicine and University Hospital Ostrava/Ostrava/Tchèque, République (8 aut.); University of Wurzburg/Wurzburg/Allemagne (9 aut.); Dana-Farber Cancer Institute/Boston, MA/Etats-Unis (10 aut., 12 aut.); University of Athens School of Medicine/Athens/Grèce (11 aut.); Alfred Hospital/Melbourne, Victoria/Australie (14 aut.); Mayo Clinic/Scottsdale, AZ/Etats-Unis (15 aut.); Aichi Gakuin Hospital/Nagoya/Japon (16 aut.); Emory University/Atlanta, GA/Etats-Unis (17 aut.); Erasmus Medical Centre/Rotterdam/Pays-Bas (18 aut.); Cedars-Sinai Comprehensive Cancer Center/Los Angeles, CA/Etats-Unis (19 aut.); University Hospital/Nantes/France (20 aut.); MD Anderson Cancer Center/Houston, TX/Etats-Unis (21 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Journal of clinical oncology; ISSN 0732-183X; Etats-Unis; Da. 2014; Vol. 32; No. 6; Pp. 587-600; Bibl. 122 ref. |
| LA : | Anglais |
| EA : | Purpose To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. Methods A comprehensive review of the literature on diagnostic criteria is provided, and treatment options and management of adverse events are summarized. Results Patients with symptomatic disease and organ damage (ie, hypercalcemia, renal failure, anemia, or bone lesions) require immediate treatment. The International Staging System and chromosomal abnormalities identify high- and standard-risk patients. Proteasome inhibitors, immunomodulatory drugs, corticosteroids, and alkylating agents are the most active agents. The presence of concomitant diseases, frailty, or disability should be assessed and, if present, treated with reduced-dose approaches. Bone disease, renal damage, hematologic toxicities, infections, thromboembolism, and peripheral neuropathy are the most frequent disabling events requiring prompt and active supportive care. Conclusion These recommendations will help clinicians ensure the most appropriate care for patients with myeloma in everyday clinical practice. |
| CC : | 002B04; 002B06D02 |
| FD : | Myélome; International; Consensus; Conduite à tenir; Traitement; Soin de support; Homme; Norme; Cellule hématopoïétique; Cellule souche; Cancérologie; Hémopathie maligne lymphoïde; Hémopathie lymphoïde B; Autogreffe de cellules souches hématopoïétiques |
| FG : | Hémopathie maligne; Cancer; Immunoglobulinopathie; Syndrome lymphoprolifératif; Immunopathologie |
| ED : | Myeloma; International; Consensus; Clinical management; Treatment; Supportive care; Human; Standards; Hematopoietic cell; Stem cell; Cancerology; Lymphoid neoplasm; B cell neoplasm; Autologous hematopoietic stem cell transplantation |
| EG : | Malignant hemopathy; Cancer; Immunoglobulinopathy; Lymphoproliferative syndrome; Immunopathology |
| SD : | Mieloma; Internacional; Consenso; Actitud médica; Tratamiento; Cuidado de soporte; Hombre; Norma; Célula hematopoyética; Célula primitiva; Cancerología; Autoinjerto de células precursoras hematopoyéticas |
| LO : | INIST-20094.354000505776350170 |
| ID : | 14-0114004 |
Links to Exploration step
Pascal:14-0114004Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation</title><author><name sortKey="Palumbo, Antonio" sort="Palumbo, Antonio" uniqKey="Palumbo A" first="Antonio" last="Palumbo">Antonio Palumbo</name><affiliation><inist:fA14 i1="01"><s1>University of Torino</s1><s2>Torino</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Vincent Rajkumar, S" sort="Vincent Rajkumar, S" uniqKey="Vincent Rajkumar S" first="S." last="Vincent Rajkumar">S. Vincent Rajkumar</name><affiliation><inist:fA14 i1="03"><s1>Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="San Miguel, Jesus F" sort="San Miguel, Jesus F" uniqKey="San Miguel J" first="Jesus F." last="San Miguel">Jesus F. San Miguel</name><affiliation><inist:fA14 i1="04"><s1>University Hospital of Salamanca</s1><s2>Salamanca</s2><s3>ESP</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Larocca, Alessandra" sort="Larocca, Alessandra" uniqKey="Larocca A" first="Alessandra" last="Larocca">Alessandra Larocca</name><affiliation><inist:fA14 i1="01"><s1>University of Torino</s1><s2>Torino</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Niesvizky, Ruben" sort="Niesvizky, Ruben" uniqKey="Niesvizky R" first="Ruben" last="Niesvizky">Ruben Niesvizky</name><affiliation><inist:fA14 i1="05"><s1>Weill Cornell Medical College</s1><s2>New York, NY</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Morgan, Gareth" sort="Morgan, Gareth" uniqKey="Morgan G" first="Gareth" last="Morgan">Gareth Morgan</name><affiliation><inist:fA14 i1="06"><s1>Royal Marsden Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Landgren, Ola" sort="Landgren, Ola" uniqKey="Landgren O" first="Ola" last="Landgren">Ola Landgren</name><affiliation><inist:fA14 i1="07"><s1>National Cancer Institute</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hajek, Roman" sort="Hajek, Roman" uniqKey="Hajek R" first="Roman" last="Hajek">Roman Hajek</name><affiliation><inist:fA14 i1="08"><s1>University of Ostrava School of Medicine and University Hospital Ostrava</s1><s2>Ostrava</s2><s3>CZE</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Einsele, Hermann" sort="Einsele, Hermann" uniqKey="Einsele H" first="Hermann" last="Einsele">Hermann Einsele</name><affiliation><inist:fA14 i1="09"><s1>University of Wurzburg</s1><s2>Wurzburg</s2><s3>DEU</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Anderson, Kenneth C" sort="Anderson, Kenneth C" uniqKey="Anderson K" first="Kenneth C." last="Anderson">Kenneth C. Anderson</name><affiliation><inist:fA14 i1="10"><s1>Dana-Farber Cancer Institute</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>10 aut.</sZ><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A." last="Dimopoulos">Meletios A. Dimopoulos</name><affiliation><inist:fA14 i1="11"><s1>University of Athens School of Medicine</s1><s2>Athens</s2><s3>GRC</s3><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Richardson, Paul G" sort="Richardson, Paul G" uniqKey="Richardson P" first="Paul G." last="Richardson">Paul G. Richardson</name><affiliation><inist:fA14 i1="10"><s1>Dana-Farber Cancer Institute</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>10 aut.</sZ><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Cavo, Michele" sort="Cavo, Michele" uniqKey="Cavo M" first="Michele" last="Cavo">Michele Cavo</name><affiliation><inist:fA14 i1="02"><s1>Seragnoli Institute of Hematology, Bologna University School of Medicine</s1><s2>Bologna</s2><s3>ITA</s3><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name><affiliation><inist:fA14 i1="12"><s1>Alfred Hospital</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Keith Stewart, A" sort="Keith Stewart, A" uniqKey="Keith Stewart A" first="A." last="Keith Stewart">A. Keith Stewart</name><affiliation><inist:fA14 i1="13"><s1>Mayo Clinic</s1><s2>Scottsdale, AZ</s2><s3>USA</s3><sZ>15 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Shimizu, Kazuyuki" sort="Shimizu, Kazuyuki" uniqKey="Shimizu K" first="Kazuyuki" last="Shimizu">Kazuyuki Shimizu</name><affiliation><inist:fA14 i1="14"><s1>Aichi Gakuin Hospital</s1><s2>Nagoya</s2><s3>JPN</s3><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lonial, Sagar" sort="Lonial, Sagar" uniqKey="Lonial S" first="Sagar" last="Lonial">Sagar Lonial</name><affiliation><inist:fA14 i1="15"><s1>Emory University</s1><s2>Atlanta, GA</s2><s3>USA</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sonneveld, Pieter" sort="Sonneveld, Pieter" uniqKey="Sonneveld P" first="Pieter" last="Sonneveld">Pieter Sonneveld</name><affiliation><inist:fA14 i1="16"><s1>Erasmus Medical Centre</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Durie, Brian G M" sort="Durie, Brian G M" uniqKey="Durie B" first="Brian G. M." last="Durie">Brian G. M. Durie</name><affiliation><inist:fA14 i1="17"><s1>Cedars-Sinai Comprehensive Cancer Center</s1><s2>Los Angeles, CA</s2><s3>USA</s3><sZ>19 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Moreau, Philippe" sort="Moreau, Philippe" uniqKey="Moreau P" first="Philippe" last="Moreau">Philippe Moreau</name><affiliation><inist:fA14 i1="18"><s1>University Hospital</s1><s2>Nantes</s2><s3>FRA</s3><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name><affiliation><inist:fA14 i1="19"><s1>MD Anderson Cancer Center</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>21 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0114004</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0114004 INIST</idno><idno type="RBID">Pascal:14-0114004</idno><idno type="wicri:Area/PascalFrancis/Corpus">000471</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation</title><author><name sortKey="Palumbo, Antonio" sort="Palumbo, Antonio" uniqKey="Palumbo A" first="Antonio" last="Palumbo">Antonio Palumbo</name><affiliation><inist:fA14 i1="01"><s1>University of Torino</s1><s2>Torino</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Vincent Rajkumar, S" sort="Vincent Rajkumar, S" uniqKey="Vincent Rajkumar S" first="S." last="Vincent Rajkumar">S. Vincent Rajkumar</name><affiliation><inist:fA14 i1="03"><s1>Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="San Miguel, Jesus F" sort="San Miguel, Jesus F" uniqKey="San Miguel J" first="Jesus F." last="San Miguel">Jesus F. San Miguel</name><affiliation><inist:fA14 i1="04"><s1>University Hospital of Salamanca</s1><s2>Salamanca</s2><s3>ESP</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Larocca, Alessandra" sort="Larocca, Alessandra" uniqKey="Larocca A" first="Alessandra" last="Larocca">Alessandra Larocca</name><affiliation><inist:fA14 i1="01"><s1>University of Torino</s1><s2>Torino</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Niesvizky, Ruben" sort="Niesvizky, Ruben" uniqKey="Niesvizky R" first="Ruben" last="Niesvizky">Ruben Niesvizky</name><affiliation><inist:fA14 i1="05"><s1>Weill Cornell Medical College</s1><s2>New York, NY</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Morgan, Gareth" sort="Morgan, Gareth" uniqKey="Morgan G" first="Gareth" last="Morgan">Gareth Morgan</name><affiliation><inist:fA14 i1="06"><s1>Royal Marsden Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Landgren, Ola" sort="Landgren, Ola" uniqKey="Landgren O" first="Ola" last="Landgren">Ola Landgren</name><affiliation><inist:fA14 i1="07"><s1>National Cancer Institute</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hajek, Roman" sort="Hajek, Roman" uniqKey="Hajek R" first="Roman" last="Hajek">Roman Hajek</name><affiliation><inist:fA14 i1="08"><s1>University of Ostrava School of Medicine and University Hospital Ostrava</s1><s2>Ostrava</s2><s3>CZE</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Einsele, Hermann" sort="Einsele, Hermann" uniqKey="Einsele H" first="Hermann" last="Einsele">Hermann Einsele</name><affiliation><inist:fA14 i1="09"><s1>University of Wurzburg</s1><s2>Wurzburg</s2><s3>DEU</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Anderson, Kenneth C" sort="Anderson, Kenneth C" uniqKey="Anderson K" first="Kenneth C." last="Anderson">Kenneth C. Anderson</name><affiliation><inist:fA14 i1="10"><s1>Dana-Farber Cancer Institute</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>10 aut.</sZ><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A." last="Dimopoulos">Meletios A. Dimopoulos</name><affiliation><inist:fA14 i1="11"><s1>University of Athens School of Medicine</s1><s2>Athens</s2><s3>GRC</s3><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Richardson, Paul G" sort="Richardson, Paul G" uniqKey="Richardson P" first="Paul G." last="Richardson">Paul G. Richardson</name><affiliation><inist:fA14 i1="10"><s1>Dana-Farber Cancer Institute</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>10 aut.</sZ><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Cavo, Michele" sort="Cavo, Michele" uniqKey="Cavo M" first="Michele" last="Cavo">Michele Cavo</name><affiliation><inist:fA14 i1="02"><s1>Seragnoli Institute of Hematology, Bologna University School of Medicine</s1><s2>Bologna</s2><s3>ITA</s3><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name><affiliation><inist:fA14 i1="12"><s1>Alfred Hospital</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Keith Stewart, A" sort="Keith Stewart, A" uniqKey="Keith Stewart A" first="A." last="Keith Stewart">A. Keith Stewart</name><affiliation><inist:fA14 i1="13"><s1>Mayo Clinic</s1><s2>Scottsdale, AZ</s2><s3>USA</s3><sZ>15 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Shimizu, Kazuyuki" sort="Shimizu, Kazuyuki" uniqKey="Shimizu K" first="Kazuyuki" last="Shimizu">Kazuyuki Shimizu</name><affiliation><inist:fA14 i1="14"><s1>Aichi Gakuin Hospital</s1><s2>Nagoya</s2><s3>JPN</s3><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lonial, Sagar" sort="Lonial, Sagar" uniqKey="Lonial S" first="Sagar" last="Lonial">Sagar Lonial</name><affiliation><inist:fA14 i1="15"><s1>Emory University</s1><s2>Atlanta, GA</s2><s3>USA</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sonneveld, Pieter" sort="Sonneveld, Pieter" uniqKey="Sonneveld P" first="Pieter" last="Sonneveld">Pieter Sonneveld</name><affiliation><inist:fA14 i1="16"><s1>Erasmus Medical Centre</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Durie, Brian G M" sort="Durie, Brian G M" uniqKey="Durie B" first="Brian G. M." last="Durie">Brian G. M. Durie</name><affiliation><inist:fA14 i1="17"><s1>Cedars-Sinai Comprehensive Cancer Center</s1><s2>Los Angeles, CA</s2><s3>USA</s3><sZ>19 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Moreau, Philippe" sort="Moreau, Philippe" uniqKey="Moreau P" first="Philippe" last="Moreau">Philippe Moreau</name><affiliation><inist:fA14 i1="18"><s1>University Hospital</s1><s2>Nantes</s2><s3>FRA</s3><sZ>20 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z." last="Orlowski">Robert Z. Orlowski</name><affiliation><inist:fA14 i1="19"><s1>MD Anderson Cancer Center</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>21 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Autologous hematopoietic stem cell transplantation</term><term>B cell neoplasm</term><term>Cancerology</term><term>Clinical management</term><term>Consensus</term><term>Hematopoietic cell</term><term>Human</term><term>International</term><term>Lymphoid neoplasm</term><term>Myeloma</term><term>Standards</term><term>Stem cell</term><term>Supportive care</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Myélome</term><term>International</term><term>Consensus</term><term>Conduite à tenir</term><term>Traitement</term><term>Soin de support</term><term>Homme</term><term>Norme</term><term>Cellule hématopoïétique</term><term>Cellule souche</term><term>Cancérologie</term><term>Hémopathie maligne lymphoïde</term><term>Hémopathie lymphoïde B</term><term>Autogreffe de cellules souches hématopoïétiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Purpose To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. Methods A comprehensive review of the literature on diagnostic criteria is provided, and treatment options and management of adverse events are summarized. Results Patients with symptomatic disease and organ damage (ie, hypercalcemia, renal failure, anemia, or bone lesions) require immediate treatment. The International Staging System and chromosomal abnormalities identify high- and standard-risk patients. Proteasome inhibitors, immunomodulatory drugs, corticosteroids, and alkylating agents are the most active agents. The presence of concomitant diseases, frailty, or disability should be assessed and, if present, treated with reduced-dose approaches. Bone disease, renal damage, hematologic toxicities, infections, thromboembolism, and peripheral neuropathy are the most frequent disabling events requiring prompt and active supportive care. Conclusion These recommendations will help clinicians ensure the most appropriate care for patients with myeloma in everyday clinical practice.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0732-183X</s0></fA01><fA03 i2="1"><s0>J. clin. oncol.</s0></fA03><fA05><s2>32</s2></fA05><fA06><s2>6</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation</s1></fA08><fA11 i1="01" i2="1"><s1>PALUMBO (Antonio)</s1></fA11><fA11 i1="02" i2="1"><s1>VINCENT RAJKUMAR (S.)</s1></fA11><fA11 i1="03" i2="1"><s1>SAN MIGUEL (Jesus F.)</s1></fA11><fA11 i1="04" i2="1"><s1>LAROCCA (Alessandra)</s1></fA11><fA11 i1="05" i2="1"><s1>NIESVIZKY (Ruben)</s1></fA11><fA11 i1="06" i2="1"><s1>MORGAN (Gareth)</s1></fA11><fA11 i1="07" i2="1"><s1>LANDGREN (Ola)</s1></fA11><fA11 i1="08" i2="1"><s1>HAJEK (Roman)</s1></fA11><fA11 i1="09" i2="1"><s1>EINSELE (Hermann)</s1></fA11><fA11 i1="10" i2="1"><s1>ANDERSON (Kenneth C.)</s1></fA11><fA11 i1="11" i2="1"><s1>DIMOPOULOS (Meletios A.)</s1></fA11><fA11 i1="12" i2="1"><s1>RICHARDSON (Paul G.)</s1></fA11><fA11 i1="13" i2="1"><s1>CAVO (Michele)</s1></fA11><fA11 i1="14" i2="1"><s1>SPENCER (Andrew)</s1></fA11><fA11 i1="15" i2="1"><s1>KEITH STEWART (A.)</s1></fA11><fA11 i1="16" i2="1"><s1>SHIMIZU (Kazuyuki)</s1></fA11><fA11 i1="17" i2="1"><s1>LONIAL (Sagar)</s1></fA11><fA11 i1="18" i2="1"><s1>SONNEVELD (Pieter)</s1></fA11><fA11 i1="19" i2="1"><s1>DURIE (Brian G. M.)</s1></fA11><fA11 i1="20" i2="1"><s1>MOREAU (Philippe)</s1></fA11><fA11 i1="21" i2="1"><s1>ORLOWSKI (Robert Z.)</s1></fA11><fA14 i1="01"><s1>University of Torino</s1><s2>Torino</s2><s3>ITA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></fA14><fA14 i1="02"><s1>Seragnoli Institute of Hematology, Bologna University School of Medicine</s1><s2>Bologna</s2><s3>ITA</s3><sZ>13 aut.</sZ></fA14><fA14 i1="03"><s1>Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="04"><s1>University Hospital of Salamanca</s1><s2>Salamanca</s2><s3>ESP</s3><sZ>3 aut.</sZ></fA14><fA14 i1="05"><s1>Weill Cornell Medical College</s1><s2>New York, NY</s2><s3>USA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>Royal Marsden Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>6 aut.</sZ></fA14><fA14 i1="07"><s1>National Cancer Institute</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>7 aut.</sZ></fA14><fA14 i1="08"><s1>University of Ostrava School of Medicine and University Hospital Ostrava</s1><s2>Ostrava</s2><s3>CZE</s3><sZ>8 aut.</sZ></fA14><fA14 i1="09"><s1>University of Wurzburg</s1><s2>Wurzburg</s2><s3>DEU</s3><sZ>9 aut.</sZ></fA14><fA14 i1="10"><s1>Dana-Farber Cancer Institute</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>10 aut.</sZ><sZ>12 aut.</sZ></fA14><fA14 i1="11"><s1>University of Athens School of Medicine</s1><s2>Athens</s2><s3>GRC</s3><sZ>11 aut.</sZ></fA14><fA14 i1="12"><s1>Alfred Hospital</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>14 aut.</sZ></fA14><fA14 i1="13"><s1>Mayo Clinic</s1><s2>Scottsdale, AZ</s2><s3>USA</s3><sZ>15 aut.</sZ></fA14><fA14 i1="14"><s1>Aichi Gakuin Hospital</s1><s2>Nagoya</s2><s3>JPN</s3><sZ>16 aut.</sZ></fA14><fA14 i1="15"><s1>Emory University</s1><s2>Atlanta, GA</s2><s3>USA</s3><sZ>17 aut.</sZ></fA14><fA14 i1="16"><s1>Erasmus Medical Centre</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>18 aut.</sZ></fA14><fA14 i1="17"><s1>Cedars-Sinai Comprehensive Cancer Center</s1><s2>Los Angeles, CA</s2><s3>USA</s3><sZ>19 aut.</sZ></fA14><fA14 i1="18"><s1>University Hospital</s1><s2>Nantes</s2><s3>FRA</s3><sZ>20 aut.</sZ></fA14><fA14 i1="19"><s1>MD Anderson Cancer Center</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>21 aut.</sZ></fA14><fA20><s1>587-600</s1></fA20><fA21><s1>2014</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20094</s2><s5>354000505776350170</s5></fA43><fA44><s0>0000</s0><s1>© 2014 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>122 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>14-0114004</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Journal of clinical oncology</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Purpose To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. Methods A comprehensive review of the literature on diagnostic criteria is provided, and treatment options and management of adverse events are summarized. Results Patients with symptomatic disease and organ damage (ie, hypercalcemia, renal failure, anemia, or bone lesions) require immediate treatment. The International Staging System and chromosomal abnormalities identify high- and standard-risk patients. Proteasome inhibitors, immunomodulatory drugs, corticosteroids, and alkylating agents are the most active agents. The presence of concomitant diseases, frailty, or disability should be assessed and, if present, treated with reduced-dose approaches. Bone disease, renal damage, hematologic toxicities, infections, thromboembolism, and peripheral neuropathy are the most frequent disabling events requiring prompt and active supportive care. Conclusion These recommendations will help clinicians ensure the most appropriate care for patients with myeloma in everyday clinical practice.</s0></fC01><fC02 i1="01" i2="X"><s0>002B04</s0></fC02><fC02 i1="02" i2="X"><s0>002B06D02</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Myélome</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Myeloma</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Mieloma</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>International</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>International</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Internacional</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Consensus</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Consensus</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Consenso</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Conduite à tenir</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Clinical management</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Actitud médica</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Traitement</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Treatment</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Tratamiento</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Soin de support</s0><s5>07</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Supportive care</s0><s5>07</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Cuidado de soporte</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Human</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Norme</s0><s5>09</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Standards</s0><s5>09</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Norma</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Cellule hématopoïétique</s0><s5>11</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Hematopoietic cell</s0><s5>11</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Célula hematopoyética</s0><s5>11</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Cellule souche</s0><s5>12</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Stem cell</s0><s5>12</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Célula primitiva</s0><s5>12</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Cancérologie</s0><s5>17</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Cancerology</s0><s5>17</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Cancerología</s0><s5>17</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Hémopathie maligne lymphoïde</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Lymphoid neoplasm</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Hémopathie lymphoïde B</s0><s4>CD</s4><s5>97</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>B cell neoplasm</s0><s4>CD</s4><s5>97</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Autogreffe de cellules souches hématopoïétiques</s0><s4>CD</s4><s5>98</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Autologous hematopoietic stem cell transplantation</s0><s4>CD</s4><s5>98</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Autoinjerto de células precursoras hematopoyéticas</s0><s4>CD</s4><s5>98</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Hémopathie maligne</s0><s2>NM</s2><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Malignant hemopathy</s0><s2>NM</s2><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Hemopatía maligna</s0><s2>NM</s2><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Cáncer</s0><s2>NM</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Immunoglobulinopathie</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Immunoglobulinopathy</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Inmunoglobulinopatía</s0><s5>38</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Syndrome lymphoprolifératif</s0><s2>NM</s2><s5>39</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Lymphoproliferative syndrome</s0><s2>NM</s2><s5>39</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Linfoproliferativo síndrome</s0><s2>NM</s2><s5>39</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Immunopathologie</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Immunopathology</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Inmunopatología</s0><s5>40</s5></fC07><fN21><s1>146</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 14-0114004 INIST</NO><ET>International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation</ET><AU>PALUMBO (Antonio); VINCENT RAJKUMAR (S.); SAN MIGUEL (Jesus F.); LAROCCA (Alessandra); NIESVIZKY (Ruben); MORGAN (Gareth); LANDGREN (Ola); HAJEK (Roman); EINSELE (Hermann); ANDERSON (Kenneth C.); DIMOPOULOS (Meletios A.); RICHARDSON (Paul G.); CAVO (Michele); SPENCER (Andrew); KEITH STEWART (A.); SHIMIZU (Kazuyuki); LONIAL (Sagar); SONNEVELD (Pieter); DURIE (Brian G. M.); MOREAU (Philippe); ORLOWSKI (Robert Z.)</AU><AF>University of Torino/Torino/Italie (1 aut., 4 aut.); Seragnoli Institute of Hematology, Bologna University School of Medicine/Bologna/Italie (13 aut.); Mayo Clinic/Rochester, MN/Etats-Unis (2 aut.); University Hospital of Salamanca/Salamanca/Espagne (3 aut.); Weill Cornell Medical College/New York, NY/Etats-Unis (5 aut.); Royal Marsden Hospital/London/Royaume-Uni (6 aut.); National Cancer Institute/Bethesda, MD/Etats-Unis (7 aut.); University of Ostrava School of Medicine and University Hospital Ostrava/Ostrava/Tchèque, République (8 aut.); University of Wurzburg/Wurzburg/Allemagne (9 aut.); Dana-Farber Cancer Institute/Boston, MA/Etats-Unis (10 aut., 12 aut.); University of Athens School of Medicine/Athens/Grèce (11 aut.); Alfred Hospital/Melbourne, Victoria/Australie (14 aut.); Mayo Clinic/Scottsdale, AZ/Etats-Unis (15 aut.); Aichi Gakuin Hospital/Nagoya/Japon (16 aut.); Emory University/Atlanta, GA/Etats-Unis (17 aut.); Erasmus Medical Centre/Rotterdam/Pays-Bas (18 aut.); Cedars-Sinai Comprehensive Cancer Center/Los Angeles, CA/Etats-Unis (19 aut.); University Hospital/Nantes/France (20 aut.); MD Anderson Cancer Center/Houston, TX/Etats-Unis (21 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Journal of clinical oncology; ISSN 0732-183X; Etats-Unis; Da. 2014; Vol. 32; No. 6; Pp. 587-600; Bibl. 122 ref.</SO><LA>Anglais</LA><EA>Purpose To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. Methods A comprehensive review of the literature on diagnostic criteria is provided, and treatment options and management of adverse events are summarized. Results Patients with symptomatic disease and organ damage (ie, hypercalcemia, renal failure, anemia, or bone lesions) require immediate treatment. The International Staging System and chromosomal abnormalities identify high- and standard-risk patients. Proteasome inhibitors, immunomodulatory drugs, corticosteroids, and alkylating agents are the most active agents. The presence of concomitant diseases, frailty, or disability should be assessed and, if present, treated with reduced-dose approaches. Bone disease, renal damage, hematologic toxicities, infections, thromboembolism, and peripheral neuropathy are the most frequent disabling events requiring prompt and active supportive care. Conclusion These recommendations will help clinicians ensure the most appropriate care for patients with myeloma in everyday clinical practice.</EA><CC>002B04; 002B06D02</CC><FD>Myélome; International; Consensus; Conduite à tenir; Traitement; Soin de support; Homme; Norme; Cellule hématopoïétique; Cellule souche; Cancérologie; Hémopathie maligne lymphoïde; Hémopathie lymphoïde B; Autogreffe de cellules souches hématopoïétiques</FD><FG>Hémopathie maligne; Cancer; Immunoglobulinopathie; Syndrome lymphoprolifératif; Immunopathologie</FG><ED>Myeloma; International; Consensus; Clinical management; Treatment; Supportive care; Human; Standards; Hematopoietic cell; Stem cell; Cancerology; Lymphoid neoplasm; B cell neoplasm; Autologous hematopoietic stem cell transplantation</ED><EG>Malignant hemopathy; Cancer; Immunoglobulinopathy; Lymphoproliferative syndrome; Immunopathology</EG><SD>Mieloma; Internacional; Consenso; Actitud médica; Tratamiento; Cuidado de soporte; Hombre; Norma; Célula hematopoyética; Célula primitiva; Cancerología; Autoinjerto de células precursoras hematopoyéticas</SD><LO>INIST-20094.354000505776350170</LO><ID>14-0114004</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000471 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000471 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:14-0114004
|texte= International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
}}
| This area was generated with Dilib version V0.6.33. |  |